🟢 Eupraxia Pharmaceuticals is trading 13% up in pre-market after Q2 report highlighted $133.7 million liquidity

Eupraxia Pharmaceuticals is trading sharply higher at $7.30, up +12.65%, after its August 11 Q2 report highlighted $133.7 million in liquidity and cash runway into the second half of 2028.

• New EP-104GI data showed improved fibrosis and inflammation after one treatment.
• Phase 2b interim data are anticipated in Q4 2026.
• The company has not reported a separate August 13 announcement or explicitly linked the move to the release.